MRG006A / Lepu Med - LARVOL DELTA

The first GPC3 ADC in China starts clinical trials [Google translation] (Sohu.com) - "On July 8, according to the official website of CDE, Lepu Biopharmaceuticals launched a Phase I/II clinical trial in China for MRG006A to evaluate its safety and tolerability in treating patients with advanced solid tumors (registration number: CTR20242454)."

Trial status • Oncology • Solid Tumor

The first GPC3 ADC in China has been submitted to clinical trials! [Google translation] (Sohu.com) - "On April 23, according to the CDE official website, Lepu Biotech’s first clinical application for MRG006A was accepted (acceptance number: CXSL2400256)....MRG006A is a new GPC3- targeted ADC drug developed by Lepu Biotechnology based on the Hi-TOPi technology platform..."

New trial • Oncology • Solid Tumor

MRG006A, a novel glypican-3-targeting antibody-drug conjugate, demonstrated potent anti-tumor activity and good safety profile in preclinical studies (AACR 2024) - "Overall, the preclinical study results suggest that MRG006A is a feasible ADC drug candidate for treating GPC3-expressing cancers in clinical studies. MRG006A was aimed to submit IND in China and the U.S in 2024."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3